机构:[1]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.[2]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.四川省人民医院四川省肿瘤医院[3]Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.[4]Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Abnormal regulation of centrosome components can induce chromosome instability and tumorigenesis. Centrosomal protein 63 (CEP63) is a vital member for assembling centrosome. Yet, the involvement of CEP63 in cancer pathogenesis remains unclear. Here we identify CEP63 as an important mediator for RNA-binding proteins (RBPs) to facilitate regulation on their RNA targets in colorectal cancer (CRC). We demonstrate that CEP63 protein is upregulated in a large cohort of colorectal cancer tissues and predicts poor prognosis, and USP36 is identified for stabilizing CEP63 by enhancing its K48-dependent deubiquitination. CEP63 overexpression promotes the proliferation and tumor growth of CRC cells in vitro and in vivo. Furthermore, we find that CEP63 can promote cancer stem-like cell properties by enhancing YAP1 expression through binding with and inhibiting the K63-ubiquitylation degradation of RBP FXR1 in CRC cells. Importantly, we further verify that the KH domain of FXR1 is necessary for the interaction between CEP63 and FXR1. Moreover, microtube motor proteins can form a complex with CEP63 and FXR1 to mediate the regulation of FXR1 on RNA targets. Additionally, we also confirm that CEP63 can bind and regulate multiple RBPs. In conclusion, our findings unveil an unrecognized CEP63/RBPs/RNA axis that CEP63 may perform as an adapter facilitating the formation of RBPs complex to regulate RNA progression and discover the role of CEP63 involved in signal transduction and RNA regulation, providing potential therapeutic target for CRC patients.
基金:
This work was supported by grants from the National Key R&D Program of China
(grant number 2021YFA1300201); the National Natural Science Foundation of China
(grant numbers 81972227, 81730072, 82072608, 81872001, 81903007 and 82002467);
the Guangzhou Science and Technology Plan Projects (grant number 201904020044)
and the China Postdoctoral Science Foundation (2020M672999).
第一作者机构:[1]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
共同第一作者:
通讯作者:
通讯机构:[1]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.[4]Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
推荐引用方式(GB/T 7714):
Ling Han,Cao Chen-Hui,Han Kai,et al.CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1[J].ONCOGENE.2022,41(39):4433-4445.doi:10.1038/s41388-022-02439-y.
APA:
Ling, Han,Cao, Chen-Hui,Han, Kai,Lv, Yong-Rui,Ma, Xiao-Dan...&Wang, Feng-Wei.(2022).CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1.ONCOGENE,41,(39)
MLA:
Ling, Han,et al."CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1".ONCOGENE 41..39(2022):4433-4445